Myeloma criteria

For patients with precursor disease to multiple myeloma (MM), the standard for predicting disease progression is the risk stratification criteria from the International Myeloma Working Group (IMWG). These criteria put patients into one of four risk groups – low, low-intermediate, high-intermediate, or high – based on information

People with one or more of the criteria listed above are considered active myeloma patients, as those with smoldering myeloma do not present with CRAB features. Watch the video below for more information on how active myeloma is defined.

Revised International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma. Both of the following criteria must be met: Malignant plasma cells in the bone

The C.R.A.B criteria defines certain symptoms of multiple myeloma, such as calcium elevation. They are an important tool that doctors use to help diagnose multiple myeloma and determine its

ᅟ: FDG PET/CT (18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM).However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine experts defined new visual descriptive criteria (Italian Myeloma criteria

The Italian myeloma criteria for PET use (IMPeTUs) were proposed to standardize FDG PET/CT reading in multiple myeloma. In this communication an overview on IMPeTUs is provided as well as some

2025: International Myeloma Working Group PMID Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. (International Myeloma Working Group [no authors listed], Br J Haematol. 2025 Jun;121(5): .)

The revised diagnostic criteria for multiple myeloma and smoldering multiple myeloma have been proposed by the International Myeloma Working Group. These criteria include specific requirements for bone marrow plasma cells, serum free light chain ratio, MRI findings, myeloma bone disease, renal failure, monoclonal protein, and the need for symptoms.

In 2025, the journal Leukemia published the International uniform response criteria for multiple myeloma. The following table explains the